Factor 8 Gene Roctavian denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for factor 8 gene roctavian are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Step Therapy to Roctavian — and Why You Can Appeal

Roctavian (valoctocogene roxaparvovec) is a one-time gene therapy for adults with severe hemophilia A. Despite its unique mechanism and single-administration profile, Cigna may require documented failure of, or contraindication to, specified prior therapies before approving coverage. Step-therapy denials in this context typically mean the plan wants documented evidence that the patient has been managed with established factor-replacement or extended-half-life factor products — and that continued standard therapy is inadequate — before authorizing a gene-therapy approach.

## Why This Denial Is Appealable

Step-therapy requirements must be clinically appropriate and cannot override a prescriber's professional judgment when prior therapies have genuinely failed or are not suitable. Many states have enacted step-therapy reform laws requiring plans to grant exceptions when the required prior therapy is contraindicated, has been tried and failed, or when requiring it would cause clinically significant harm. For self-funded ERISA plans, federal law still requires the step-therapy standard to be applied consistently with current clinical evidence and the plan's own written criteria.

## Federal Appeal Framework

• ERISA §503: Full-and-fair internal review required. File within 180 days of the denial notice.
• ACA §2719: After internal exhaustion, independent external review is available — typically within four months of a final internal denial.
• Expedited option: If the patient is at imminent risk of serious bleeding or joint destruction, request expedited internal review (72-hour turnaround) and note the clinical urgency explicitly.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter and identify precisely which step-therapy criteria Cigna says have not been met. 2. Request Cigna's full written coverage policy for Roctavian, including all step-therapy prerequisites. 3. Assemble documentation showing the patient's history with each required prior therapy. 4. File the internal appeal with a structured criteria-mapping letter. 5. If denied internally, escalate to independent external review within four months.

## Documentation to Gather

• Prior-therapy history: Dates, product names, dosing regimens, duration, and outcomes for every prior hemophilia A treatment — especially any factor products specified in Cigna's policy.
• Failure or inadequacy evidence: Breakthrough bleeding events, inhibitor development records, or intolerance documentation tied to prior therapies.
• Diagnosis and severity: Genetic confirmation of severe hemophilia A; annualized bleed rate; joint damage imaging or orthopedic assessments.
• AAV vector immunity results: Pre-treatment antibody testing per the FDA-approved prescribing label.
• Prescriber medical-necessity letter: The treating hematologist should directly address each step-therapy requirement in Cigna's policy, explain why prior therapy was inadequate or not appropriate, and cite the relevant guideline organization (e.g., the applicable WFH or ASH guideline) without asserting specific numbers.

## Criteria-Mapping Structure

Print Cigna's step-therapy requirements verbatim. For each requirement, provide the chart document, date, and exact finding that satisfies it. For any requirement the plan claims is unmet, explain in clinical detail why prior therapy cannot satisfy it or why requiring it would be clinically inappropriate for this patient. This one-to-one mapping is the backbone of an effective step-therapy appeal.